A study in advanced KRAS-mutated lung cancer by Arbour et al. showed that KEAP1 co-mutations are independent prognostic markers for poorer survival (HR = 1.96; p < 0.001) and are associated with less response to chemotherapy (HR = 1.64; p = 0.03) and immunotherapy (HR = 3.54; p = 0.003) [23]. The gene discussed is KRAS; the disease is lung cancer.